中国临床药学杂志

参考文献

[1] Pfizer. FDA approves Pfizer’s LITFULO?(ritlecitinib)foradults and adolescents with se-vere alopecia areata[EB/OL].(2023-06-23)[2023-09-11]. https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-litfulotm-ritlecitinibadults-and.

[2]章星琪.国内外斑秃诊疗共识、指南的解读与启示[J].皮肤性病诊疗学杂志, 2021, 28(6):431.

[3]费文敏,李可可,李承旭,等.斑秃相关精神心理合并症及其发病机制[J].皮肤科学通报, 2021, 38(2):131.

[4]李梦丽,卢诚,万慧阳,等.小分子Janus激酶抑制剂的研究进展[J].中国新药杂志, 2021, 30(23):2178.

[5] KING B A, CRAIGLOW B G. Janus kinase inhibitors for alopecia areata[J]. J Am Acad Dermatol, 2023, 89(2S):S29.

[6] European Medicines Agency. Litfulo[EB/OL].(2023-09-18)[2024-08-14]. https://www.em-a.europa.eu/en/medicines/human/EPAR/litfulo.

[7]国家药品监督管理局.国家药监局批准甲苯磺酸利特昔替尼胶囊上市[EB/OL].(2023-10-19)[2024-08-14]. https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20231019161001181.html.

[8] Pfizer Inc. LITFULO?(ritlecitinib)capsules, for oral use:USprescribing information[EB/OL].(2023-06-23)[2023-0 9-11]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215830s000lbl.pdf.

[9] DAI Z P, CHEN J, CHANG Y Q, et al. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata[J]. JCI Insight, 2021, 6(7):e142205.

[10] GILHAR A, PAUS R, KALISH R S. Lymphocytes, neuropeptides,and genes involved in alopecia areata[J]. J Clin Invest, 2007,117(8):2019.

[11] XU H, JESSON M I, SENEVIRATNE U I, et al. PF-06651600, a dual JAK3/TEC family kinase inhibitor[J]. ACS Chem Biol,2019, 14(6):1235.

[12] THORARENSEN A, DOWTY M E, BANKER M E, et al. Design of a Janus kinase 3(JAK3)specific inhibitor 1-((2S, 5R)-5-((7HPyrrolo[2, 3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one(PF-06651600)allowing for the interrogation of jak3 signaling in humans[J]. J Med Chem, 2017, 60(5):1971.

[13] EISMAN S, SINCLAIR R. Ritlecitinib:an investigational drug for the treatment of moderate to severe alopecia areata[J]. Expert Opin Investig Drugs, 2021, 30(12):1169.

[14] LIU J, SOLAN R, WOLK R, et al. Evaluation of the effect of ritlecitinib on the pharmacokinetics of caffeine in healthy participants[J]. Br J Clin Pharmacol, 2023, 89(7):2208.

[15] KING B, ZHANG X Q, HARCHA W G, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata:a randomised, double-blind, multicentre, phase 2b-3 trial[J].Lancet, 2023, 401(10387):1518.

[16] KING B A, MIRMIRANI P, LOSICCO K, et al. Individual SALT score trajectories of de novo patients with alopecia areata(AA)treated with ritlecitinib in the ongoing phase 3, long-term, openlabel ALLEGRO-LT study[J]. J Invest Dermatol, 2023, 143(9):B15.

[17] 25th World Congress of Dermatology. Long-term safety and efficacy of ritlecitinib in pa-tients with alopecia areata:interim results from the ALLEGRO-LT phase 3,open-label study[EB/OL].(2023-07-06)[2023-09-11]. https://www.wcd2023singapore-abs.org/abstract_details.php?aid=2125.

[18] 25th World Congress of Dermatology. Long-term efficacy of ritlecitinib up to Month 24:integrated analysis of the ALLEGRO phase 2b/3 and long-term phase 3 clinical studies in alopecia areata(AA)[EB/OL].(2023-07-06)[2023-09-11]. https://www.wcd2023singapore-abs.org/abstract_details.php?aid=20114.

[19] EZZEDINE K, PEEVA E, YAMAGUCHI Y, et al. Efficacy and safetyof oral ritlecitinib for the treatment of active nonsegmental vitiligo:a randomized phase 2b clinical trial[J]. J Am Acad Dermatol, 2023, 88(2):395.

[20] NIH. Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease[EB/OL].(2023-09-08)[2023-09-11]. https://clinicaltrials.gov/study/NCT03395184?term=NCT03395184&ra nk=1.

[21] SANDBORN W J, DANESE S, LESZCZYSZYN J, et al. Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis:results from a randomized, phase 2b study[J]. Clin Gastroenterol Hepatol, 2023, 21(10):2616.

[22]李彤,刘颖,叶连宝.小分子Janus激酶抑制剂研究进展[J].药学进展, 2023, 47(3):207.

[23]李丹,赵晓娟,赵永红,等.首个重度斑秃全身疗法的新型靶向药:巴瑞替尼[J].临床药物治疗杂志, 2022, 20(12):56.

[24]袁伟,徐飞,杨君义.新型治疗类风湿关节炎药物:Janus激酶抑制剂巴瑞替尼[J].中国新药与临床杂志, 2017, 36(10):582.

[25] TELLIEZ J B, DOWTY M E, WANG L, et al. Discovery of a JAK3-Selective Inhibitor:functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition[J].ACS Chem Biol, 2016, 11(12):3442.

[26] CHOY E H. Clinical significance of Janus Kinase inhibitor selectivity[J]. Rheumatology(Oxford), 2019, 58(6):953.

[27] HUSEIN-ELAHMED H, HUSEIN-ELAHMED S. Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata:a systematic review and Bayesian network metaanalysis[J]. J Eur Acad Dermatol Venereol, 2024, 38(5):835.

[28] GUAN R X, LIN Y L, ZHANG C, et al. Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata:a systematic review and network meta-analysis[J]. Arch Dermatol Res, 2024, 316(7):483.

[29] YAN T, WANG T, TANG M, et al. Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata:a systematic review and network meta-analysis[J]. Front Pharmacol, 2024, 4(15):1372810.